Best candidates for adjunctive regenerative therapy
Patients with persistent pulmonary dysfunction, fibrotic changes, or reduced functional capacity following ARDS secondary to pneumonia or viral illness who have completed the acute phase of treatment. Ideal candidates present with evidence of degenerative fibroproliferative phase, impaired gas exchange, and reduced quality of life despite optimal conventional management. Individuals with stable or slowly progressive disease, without active malignancy or uncontrolled systemic infection, are considered for this integral supportive treatment.
Clinical evaluation includes pulmonary function tests, high‑resolution CT imaging, inflammatory biomarkers, and functional assessment. The therapy is intended as a complementary strategy to slow degeneration and improve physiological reserve.
Umbilical cord MSC core protocol
Our clinic employs umbilical cord‑derived mesenchymal stem cells (UC‑MSCs) as the central regenerative agent. These cells possess immunomodulatory, anti‑fibrotic, and pro‑angiogenic properties. Administered via minimally targeted intravenous and, when indicated, nebulized or regional perfusion techniques, they work to modulate persistent alveolar inflammation, reduce pathological extracellular matrix deposition, and promote endogenous repair mechanisms.
Supportive therapies include personalized physical rehabilitation to retrain respiratory musculature and improve exercise tolerance, and nutritional medicine focused on micronutrient repletion, antioxidant support, and metabolic optimization. This three‑pronged model—regenerative, physical, nutritional—is delivered via minimally invasive methods to reduce physiological burden.
Objective: slow the degenerative process, enhance functional independence, and in some observed cases, halt disease progression. Outcomes are measured via validated pulmonary indices, 6‑minute walk test, and patient‑reported quality of life metrics.